Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia.

Next Previous
X
Search
Trial Profile

A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat or Placebo When co-Administered With High Dose Statin Therapy in Subjects With Primary Hypercholesterolemia.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapaquistat (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center

    • Most Recent Events

    • 07 Apr 2022 This trial has been completed in Spain (Global end date: 06-03-2007), according to European Clinical Trials Database record
    • 06 Apr 2022 This trial has been completed in Norway (Global end date 06-03-2007), according to European Clinical Trials Database record.
    • 24 Mar 2009 Actual patient number (649) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top